Key takeaways
- FOXO4-DRI has no FDA-approved label and is not registered in any clinical trials in the available data.
- It is classified in research databases under the PubChem identifier 167312269.
- The compound is a large peptide, with a molecular formula of C228H388N86O64 and a molecular weight near 5,358.
- No adverse event reports or approved indications exist for this compound in the sources reviewed.
What FOXO4-DRI is
FOXO4-DRI is a synthetic peptide studied only in a research setting. There is no FDA-approved drug label, no approved brand name, and no established mechanism of action description from a regulatory source. Structurally, it is a large peptide built from a long chain of amino acid residues, reflected in its substantial molecular weight.
Regulatory and trial status
FOXO4-DRI has not been approved by the FDA for any use, and it carries unapproved, research-only status. The available data shows zero registered clinical trials for this compound, and no sample trial records are on file. This indicates the compound has not progressed into a documented clinical trial pipeline, based on the data reviewed.